PF-07832837 is under clinical development by Pfizer and currently in Phase I for Asthma. According to GlobalData, Phase I drugs for Asthma have a 74% phase transition success rate (PTSR) indication ...

BRUSSELS, January 6. /TASS/. The court of the Belgian city of Liege will hold a session to consider whether President of the European Commission (EC) Ursula von der Leyen has legal immunity against ...

These four S&P 500 stocks pay 6% and higher dividends, have Buy ratings at top Wall Street firms, and are offering excellent ...

Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory ...

Donald Trump’s allies have raised over $200 million to fund his inauguration, political operations, and presidential library.

Regeneron Pharmaceuticals is a strong investment with robust growth potential, fueled by FDA approvals and resilient market ...

The board of Pfizer Inc. ( NYSE:PFE ) has announced that it will be paying its dividend of $0.43 on the 7th of ...

Pfizer (NYSE: PFE) stock investors are curious about the valuation and prospects for the healthcare company. Stock prices used were the afternoon prices of Jan. 1, 2025. The video was published on Jan ...